MaaT Pharma SA, headquartered in Lyon, France, is at the forefront of developing innovative therapies that leverage the gut microbiome to modulate the immune system and enhance cancer survival rates. The company's product pipeline is robust, featuring several promising candidates currently in clinical trials.
- MaaT013: This therapy is in a pivotal phase 3 clinical trial, focusing on the treatment of acute graft versus host diseases with gastrointestinal involvement. It represents a significant step forward in addressing this challenging condition.
- MaaT033: Currently in phase 2b clinical trials, MaaT033 aims to improve survival rates in patients with acute myeloid leukemia or blood cancer who are undergoing allogeneic hematopoietic stem cell transplantation. This therapy underscores MaaT Pharma's commitment to advancing cancer treatment options.
- MaaT03X: Targeting solid tumors, MaaT03X is part of the company's efforts to expand its therapeutic reach to a broader range of cancers, highlighting the versatility of gut microbiome-driven therapies.
Founded in 2014, MaaT Pharma SA has quickly established itself as a key player in the biotechnology sector, with a focus on healthcare innovations that promise to transform patient outcomes. The company's dedication to research and development is evident in its active clinical trials and the potential of its therapies to address unmet medical needs in cancer treatment.
